A next-gen Duchenne therapy from Entrada Therapeutics fell short in an early study, as a number of companies race to make improved drugs.
A micrograph from a Duchenne patientAdobe
By Jason Mast
May 7, 2026
General Assignment Reporter
Jason Mast
While the company claimed a victory, analysts said data from a Phase 1/2 study fell short of expectations. Entrada shares…
Regenxbio plans to submit its Duchenne gene therapy for FDA approval, just a month after it said that regulators wanted to see…
Regenxbio said Thursday that its Duchenne muscular dystrophy gene therapy met the bar in a pivotal study, and it’s aiming for FDA…
Though two serious side effects muddied the results, CEO Curran Simpson expressed optimism about a clearance and claimed FDA…
Regenxbio said its experimental gene therapy for Duchenne muscular dystrophy succeeded in a trial, paving the way for a…
Satellos shares adult TRAILHEAD data on Duchenne pill SAT-3247 ahead of a potentially pivotal BASECAMP readout in children by…
